Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2275MR)

This product GTTS-WQ2275MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2275MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11873MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ8916MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ8650MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ8111MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ4905MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ8893MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ8163MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ3491MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW